Harnessing the Human Memory B Cell Response To Develop Antibody-Based Therapeutics

October 25, 2021



Immunome, Inc.
665 Stockton Drive, Suite 300 | Exton, PA 19341
610.321.3700 | www.immunome.com

Disclaimers and Forward-Looking Statements

This presentation includes certain disclosures that contain "forward-looking statements" intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding our beliefs and expectations regarding the advancement of our oncology and COVID-19 therapeutic antibody programs, execution of our regulatory, clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM-ONC-01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words "anticipate," believe," "estimate," "expect," "intend," "plan," "project," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business, operations, strategy, goals and anticipated milestones; our ability to execute on our strategy with respect to our R&D efforts, IND submissions and other regulatory filings, timing of these filings and governmental authority feedback regarding the same, initiation of clinical studies, generation of clinical data and other anticipated milestones as and when anticipated; the effectiveness of our product candidates, including the possibility that further preclinical data and any clinical trial data may be inconsistent with the data used for advancing the product candidates; our ability to fund operations; our reliance on vendors; the competitive landscape; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in our filings and reports with the SEC. Forward-looking statements contained in this document are made as of this date, and we undertake no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

This document may contain product names, trade names, trademarks and service marks of the Company and of other organizations, of which are the properties of their respective owners.

Statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this presentation, including independent market research, industry publications and surveys, governmental agencies and publicly available information. While we believe that information provides a reasonable basis for these statements, it may be limited or incomplete and we may have not independently verified it. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review or verification of, all relevant information.

We may make statements or predictions about future dates for achievement of milestones related to our programs. These statements and predictions involve risks and uncertainties based on various factors and evolution over time and, therefore, actual dates for these milestones may differ.

In this presentation and oral commentary, we may discuss our current and potential future product candidates that have not yet undergone clinical trials or been approved for marketing by the U.S. Food and Drug Administration or other governmental authority. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied. This presentation does not constitute an offering of securities of any kind.

Experienced Management Team

Purnanand Sarma, PhD
President & CEO

Former CEO of Taris Biomedical
Sold to Johnson & Johnson in 2019

Corleen Roche
Chief Financial Officer

Former US CFO Biogen
Former CFO, Global Vaccines, Wyeth/Pfizer

Dennis Giesing, PhD
Chief Development Officer

Former CSO at Taris Biomedical
Led BARDA funded pandemic flu program at MediVector

Sandra Stoneman, Esq.
Chief Legal Officer

Former Partner at Duane Morris
Life Sciences practice group leader

Mike Morin, PhD
Chief Scientist

Oversaw cancer, immunology and anti-bacterial drug discovery at Pfizer

Matthew Robinson, PhD
SVP, Research & Development

Antibody Structure Function Expert
formerly at Fox Chase Cancer Center

Immunome "At A Glance"

Proprietary Discovery Engine

Rapid, Unbiased Interrogation of Patient Memory B Cells

Applicable Across Multiple Therapeutic Areas

ADVANCING CLINICAL PROGRAMS

IMM-BCP-01 Treatment of COVID-19

IND Submission Q4 2021
Topline Data H1 2022

- Three antibody cocktail
- Binds to three non-overlapping regions of the spike protein
- ACE2 and Non ACE2 dependent neutralization
- Potent Effector Function – potential for viral clearance

IMM-ONC-01 Treatment of Solid Tumors: Targeting IL-38

IND submission Q1 2022

- Reverses IL-38 induced dampening of anti-tumor immunity
- IL38 is a novel innate immune checkpoint
- Potential indications include Lung, Head & Neck, Melanoma

ROBUST PIPELINE

Potential for multiple new programs and partnerships

- Multiple target rich areas of cancer biology
  - Membrane Dynamics/Exosomes
  - Antibody Drug Conjugates (ADCs)
- Anti-infectives
  - Rapid Response to new infections/outbreaks

Immunome Development Pipeline and Anticipated Key Milestones

ANTI-INFECTIVES	TARGET	PRODUCT CANDIDATE DESCRIPTION	DISCOVERY	PRECLINICAL	ANTICIPATED MILESTONE
IMM-BCP-01	Three SARS-CoV-2 Epitopes	Three antibody cocktail			IND filing Q4 2021

ONCOLOGY	TARGET	PRODUCT CANDIDATE DESCRIPTION	DISCOVERY	PRECLINICAL	ANTICIPATED MILESTONE
IMM-ONC-01	IL-38	Anti IL-38 antibody			IND filing Q1 2022

Proprietary Discovery Engine

Memory B cells: The Most Educated Components of Human Immune System

We see Disease Through the Lens of a B cell

Patient Sampling
Ongoing access to new and diverse patient memory B cells to feed the engine

Patient Response
Capture memory B cells from cancer or infectious disease patients

Antibody Screening
Deep, multiplexed interrogation of patient memory B cell responses

Antibody Validation
Definitive target identification and characterization of antibody - target interactions

Therapeutic Output
Unique therapeutic antibody - target pairs



Infectious Diseases

Collaboration with U.S. DoD
awarded up to $17.6M in funding



COVID - Summary

Current COVID Vaccines and Antibody Therapeutics Not Sufficient

- Breakthrough infections despite vaccine use[1]
- FDA Emergency Use Authorization of antibody therapeutics for treatment of mild to moderate COVID-19[2]
- First-generation antibody therapeutics developed based on virus neutralization to treat COVID-19[3]

IMM-BCP-01 Preclinical Testing Shows Potential to Change Standard of Care

- Three antibody cocktail with multi-modal action
  - » Strong viral neutralization and clearance *in vitro*
  - » Retains potency against key mutations, former and current CDC variants of concern (VOCs)
  - » Preclinical potency suggests potential for non-intravenous dosing in humans
  - » IND submission patient dosing anticipated in Q4 2021. Topline data in H1 2022.



1. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html
2. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs
3. Hansen et al https://www.science.org/doi/epdf/10.1126/science.abd0827 ; Jones et al DOI: 10.1126/scitranslmed.abf1906

COVID-19 Vaccines Are Effective, But Not Sufficient

COVID-19 Will Likely Remain Endemic & Specific Populations Will Continue to be at Risk

COVID surges despite ~48% of the world population receiving at least one dose of vaccine

- Recent case spike in the US even though >50% of population fully vaccinated
- Infection and death rates surged in Israel despite 70% vaccination rate

Vaccination rates across the globe are still low

- Only 2.5% of people in low-income countries have received at least one does of vaccine

Insufficient global vaccination rates continue to provide significant reservoir for viral drift



Source: ourworldindata.org/covid-vaccinations

COVID-19 Vaccines Are Effective, But Not Sufficient

Vaccines Targeting Original Strain Elicit Reduced Levels of Antibodies Capable of Neutralizing Emerging Variants

Pfizer Vaccine



AstraZeneca Vaccine



Emerging Variants Evading Antibodies Against Immunodominant Epitopes

ED50 = Neutralization titer

Planas et al Nature 596, 276-280 (2021) https://doi.org/10.1038/s41586-021-03777-9

COVID-19 Therapeutics Will Remain Critical

Variants will likely continue to emerge, and may rapidly change the landscape

- Delta variant encompasses >99% of all U.S. cases since discovery in April ‘21
- CDC monitoring 10 additional variants with substitutions of concern, including Eta, Iota, Kappa, and Mu

Evidence of decreased vaccine coverage against variants

- Increased breakthrough infection rates and transmission

Large populations will likely need therapeutic intervention

- Unvaccinated population
- High risk patients who do not derive benefit from vaccines
- Vaccinated patients with breakthrough infections



https://covid.cdc.gov/covid-data-tracker/#variant-proportions

IMM-BCP-01 Cocktail Leverages Multiple Mechanisms of Action

	IMM-BCP-01	Regen-CoV	Bamlanivimab & Etesevimab	AZD7442	Sotrovimab	ADG20
ACE2 Dependent Neutralization	✓✓	✓✓	✓✓	✓✓		✓
Non ACE2 Dependent Neutralization	✓*				✓	
Viral Clearance	✓✓✓	✓✓	✓		✓	✓
In vivo Potency (neutralization + viral clearance)	+++	+	+	+	+	+

Antibody Market Poised to Grow. Greater Efficacy and Breadth of Coverage Will Likely Drive Adoption.

- Some first-generation Abs engineered out effector function, which may reduce ability to induce viral clearance
- 1 & 2 Ab cocktails potentially susceptible to viral escape**
- Plateau of clinical benefit with escalated dose

* Immunome's antibody broadly synergizes with multiple ACE2 dependent neutralizing antibodies based on in vitro testing
** Copin et al doi.org/10.1101/2021.03.10.434834

Based on our current beliefs/opinions about selected publicly available preclinical data for other products and programs relative to IMM-BCP-01

IMM-BCP-01: Leverages Unique and Cryptic Epitopes

EPITOPE 1: IMM20253 (Non-ACE2 Dependent)

- Broadly conserved across all SARS-CoV-2 strains and other Beta coronaviruses
- Novel mechanism. Induces conformational change in Spike that enhances proteolysis and S2 release



EPITOPE 3: IMM20190 (ACE2 Dependent)

- Antibody is a potent ACE2 competitor
- A composite epitope involving the receptor binding ridge and an area adjacent to the receptor binding loop

EPITOPE 2: IMM20184 (ACE2 Dependent)

- Broadly conserved epitope across SARS-CoV-2 strains
- Antibody exhibits an avidity-based binding mechanism

Three antibody cocktail exhibits synergy across neutralization and non-neutralization mechanisms

Superior Preclinical Efficacy and Prophylactic Dose Response vs Sotrovimab

Sotrovimab
(EUA Approved at 500 mg Dose)

- Prophylactic setting (Day -1) in infected hamsters
- ~ 2-log clearance at 5mg/kg
- Dose response appears to plateau at 5 mg/kg
  - » Increasing to 30 mg/kg does not provide better efficacy



Cathcart, AL et al BioRxiv
https://doi.org/10.1101/2021.03.09.434607

IMM-BCP-01

- Prophylactic setting (Day -1) in infected hamsters
- ~2.2 log clearance at 3 mg/kg (total Ab)
- ~4 log clearance at 9 mg/kg (total Ab)
- Similar dose response obtained with Beta strain



Nikitin PA et al BioRxiv
https://doi.org/10.1101/2021.10.18.464900

Multi-Modal Activity Elicits Robust Efficacy

Infected Hamster Model in Treatment Setting

- ~3-log reduction at 3 mg/kg dose
- IMM-BCP-01 exhibits typical IgG1 clearance
  - » Dose range (3 – 15 mg/kg total Ab) yielded estimated Cmax values between 40 – 200 μg/mL (0.3 – 1.3 μM)



Nikitin PA et al BioRxiv
https://doi.org/10.1101/2021.10.18.464900

IMM-BCP-01 Neutralizes Virus Utilizing Different Mechanisms



Induces Protease Sensitive Conformation



Compete ACE2 Binding



Multiple Neutralization Mechanisms Induce Combinatorial Effect

IMM-BCP-01 is Active Across Variants

IMM-BCP-01 Acts Additively and Synergistically to Neutralize Variants[1]



	Alpha
Overall HSA score	15
Peak HSA score	61.1

1. Combinatorial effects quantified by Highest Single Agent model (HSA). Synergism (>10), additivity (-10 → 10), antagonism (<-10)

IMM-BCP-01 Neutralization of Live Virus[1]



1. Nikitin PA et al BioRxiv (https://doi.org/10.1101/2021.10.18.464900)
2. Hamster Cmax (total antibody); based upon 9 m/kg dose in hamster

IMM-BCP-01 Exhibits Broad Neutralization Pseudovirus Testing

Neutralization Across Multiple Variants[1]

Alpha, Beta, Gamma, Delta

- Current and former CDC Variants of Concern (as of 10/12/2021)

Emerging Variants

- Lambda, Mu, Delta Plus (AY.2)

US and European reference strains, USA-WA1/2020 and BavPat1/2020

Activity maintained over 20 single point and complex mutations

Potent Neutralization of Delta Variant (B.1.617.2)



1. Nikitin PA et al BioRxiv (https://doi.org/10.1101/2021.10.18.464900)
2. Hamster Cmax (total antibody); based upon 9 m/kg dose in hamster

Viral Clearance Mechanisms Are Necessary to Maintain Therapeutic Efficacy



Neutralization is not sufficient in treatment setting

» Mutating the Fc domain (LALA-PG) of anti-Spike antibodies does not alter *in vitro* neutralization potency, but destroys efficacy in a mouse treatment model of COVID-19

Neutralization



Lung Titers: 8 dpi



Survival



1. Winkler et al Cell DOI:https://doi.org/10.1016/j.cell.2021.02.026

Viral Clearance is Critical to the Treatment of Immunocompromised Patients

Immunocompromised patients lack sufficient viral clearance, resulting in prolonged viral load



Caillard, S., Benotmane, I., Vargas, G. G., Perrin, P., & Fafi-Kremer, S. (2021). SARS-CoV-2 viral dynamics in immunocompromised patients. *American Journal of Transplantation*, *21*(4), 1667–1669. https://doi.org/10.1111/ajt.16353

Prolonged Infection Leads To Emerging Resistant Variants



Caillard, S., Benotmane, I., Vargas, G. G., Perrin, P., & Fafi-Kremer, S. (2021). SARS-CoV-2 viral dynamics in immunocompromised patients. *American Journal of Transplantation*, *21*(4), 1667–1669. https://doi.org/10.1111/ajt.16353

IMM-BCP-01: Non-Neutralization Mechanisms Directed at Viral Clearance



In Vitro Data Shows Potential for Multiple Viral Clearance Mechanisms *In Vivo*

IMM-BCP-01 Elicits Potent Effector Function Driven Synergy

Complement Fixation



Phagocytosis



Antibody-Dependent Cellular Cytotoxicity





1. Hamster Cmax (total antibody); based upon 9 m/kg dose in hamster

- IMM-BCP-01 concentrations are likely to elicit maximal effector functions *in vivo*
- Each component of the cocktail contributes uniquely to effector function activity

Three antibody cocktail has the potential to offer a higher barrier to mutational drift



Literature Suggests Non-Overlapping Epitope Cocktails Offer Higher Resistance Barrier

SARS-CoV-2 rapidly escapes from individual antibodies by generating resistant mutations[1, 2, 3]

- Viral escape observed within one passage for single antibody treatments
- Escape of two antibody cocktail observed as early as passage four
- Three antibody cocktail resistant to escape beyond 11 passages

Cocktail provides stronger mutational constraints by providing multiple points of pressure

1. Ku et al Nat Commun. 2021; 12: 469 doi: 10.1038/s41467-020-20789-7
2. Baum et al Science 2020; 369:1014 doi. 10.1126/science.abd0831
3. Copin et al https://www.biorxiv.org/content/10.1101/2021.03.10.434834v4.full

IMM-BCP-01 Clinical Development Plan



IND Filing

Q4 2021

Phase 1b FIP Study

Dose Ranging

- Placebo-controlled
- Safety, PK, viral clearance by variant

Potential Phase 1b

Extension in Special Population

- Treatment and prophylaxis
- Safety, PK, viral load

Phase 2

Potential Registration Study

H2 2022

Immunome's Approach Optimized for Ideal Target Profile



Broad Activity Across Variants

- Three antibodies directed at non-overlapping/ conserved epitopes provide broad coverage

Unique Multimodal MOA

- Preclinical evidence of ACE dependent and non-dependent action; three different epitopes. Synergy against variants of concern. Clearance by phagocytosis and complement fixation

Potent *In Vivo* Activity

- Potent reduction in lung viral load in SARS-CoV-2 infected hamsters

Easy to Use

- Preclinical potency suggests efficacious dose may allow for non-Intravenous dosing

~$10B* Estimated COVID Therapeutics Market

Vaccinated Patients with Breakthrough Infection

Unvaccinated Patients

Immunocompromised Patients (~9M in the US), including:

- Transplant
- HIV
- Chemotherapy

Additional High-Risk Patients, including:

- Diabetes
- >65 years of age
- Cerebrovascular disease
- Chronic kidney disease
- COPD/Lung diseases Pregnancy and Recent Pregnancy

Antibody therapeutics are expected to have a significant market share despite vaccines and oral antivirals

* Immunome's estimate based on publicly available information

Oncology



Oncology - Summary

Highly disruptive platform discovering novel targets based on function-based interrogation of patient memory B-cell response to tumors

- Broad, deep and unbiased interrogation
- Operating at industrial scale; ~1300 hits, >50 novel targets/antibodies to-date
- Platform highlighting disease relevant functional clusters

IND filing for lead program (IMM-ONC-01) expected Q1 2022

- Targets IL-38 a novel, innate immune checkpoint which dampens anti-tumor immunity
- Preclinical data validates mechanism; pre-clinical efficacy demonstrated as a single agent
- High expression observed in multiple cancers, notably head & neck, lung and melanoma

Rich Pipeline with potential for proprietary and partnership opportunities in research/lead development stage

- Novel targets with potential to enable multiple ADC opportunities
- Target rich areas of novel cancer biology (e.g. exosome targeting)



Novel Targets

Antibodies from Patient Memory B-cells Reveal Novel Therapeutic Targets



Novel Insights from Discovery Engine

Systematic Mining of Antibodies Reveal Disease Relevant Functional Clusters

A Highly Productive Platform

300,000
HYBRIDOMAS

1,300
HITS

>50
ANTIBODY / ANTIGEN PAIRS[3]



- Provides Critical Insights Into Cancer Biology Such As:
- Membrane dynamics
- Exosome control of the tumor microenvironment1-2
- Novel immune checkpoints that serve as functional, tumor-derived inhibitors of immunity

1. Adv Clin Chem. 2016;74:103-41.DOI: 10.1016/bs.acc.2015.12.005
2. Mol Cancer. 2019 Oct 23;18(1):146. doi: 10.1186/s12943-019-1074-3
3. Including some commercially-validated targets such as ERBB2

Immunome Oncology R&D Pipeline

Targets Identified from Patient Antibodies

Program	Novel Immune Modulators	Potential Cancers of Relevance	Stage/Format
IMM-ONC-01 (Anti-IL-38)	Neutralize apoptotic tumor cells derived IL-38; recruit and activate immune cells	Lung, head and neck, melanoma, and prostate	Development / mAb

Target Research → **Lead Identification** → **Lead Optimization** → **Pre-clinical**

Program	Membrane Dynamics, Exosomes	Potential Cancers of Relevance	Stage/Format
IMM20059	Block PD-L1 on exosomes expressing novel target; reactivate exhausted anti-tumor T cells	PD-L1 resistant melanoma and prostate	Lead ID / Bi-specific

Target Research → **Lead Identification**

Program	Tumor Targeting	Potential Cancers of Relevance	Stage
IMM20326	Direct killing of tumors expressing target on surface	Chemoresistant HCC, NSCLC and ovarian	Lead ID / ADC

Target Research → **Lead Identification**

IMM20065	Direct killing of tumors expressing target on surface	Lung, cervical, CRC, breast	Research / ADC

Target Research

IL-38: A Novel Oncology Target

IL-38 Dampens Innate Anti-Tumor Immunity

IL-38

AGONISTS	ANTAGONISTS
IL36α IL36β IL36γ	IL36Ra IL38
Autoimmunity	Immune Suppression

- IL-38 is an IL-1 cytokine family member, but most closely resembles the natural antagonists of the family (IL-1Ra and IL-36a)

Typical Inflammatory Anti-tumor Response



- IL-38 inhibits infiltration & pro-inflammatory activity of innate immune cells (e.g., MΦ, γδT cells, DCs)
- IL-38 inhibits innate immune responses by dendritic cell precursors, macrophages

Clinical Consequences of IL-38 Expression

Potential for IL-38 Combination Studies with Existing Therapies

Inverse Relationship Between IL-38 Expression and Immune Cell Infiltration in Tumors

RESEARCH ARTICLE

Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression

Kazuki Takada[1,2], Tatsuro Okamoto[1]*, Masaki Tominaga[3], Koji Teraishi[1], Takaki Akamine[1], Shinkichi Takamori[1], Masakazu Katsura[1], Gouji Toyokawa[1], Fumihiro Shoji[1], Masaki Okamoto[3], Yoshinao Oda[2], Tomoaki Hoshino[3], Yoshihiko Maehara[1]



Tumor Cells Secrete IL-38 Upon Apoptosis Induction

- IL-38 secretion associated with apoptotic cell death[1]
- Acts during tissue damage to limit unwanted immune activation[2]
- Tumor cells secrete IL-38 during apoptosis *in vitro*



- Rational combination with chemotherapies that induce apoptosis in tumors

1. Mora et al, 2016. *J. Cell Mol. Cell Biol.* 2016;8 (5):426
2. Wei et al. *J. Cell Mol. Med.* 2016;00 :1

IL-38 Expression in Solid Tumors

IL-38 is Expressed in Multiple Tumors of High Unmet Medical Need

IL-38 is Expressed in Multiple Tumors of High Unmet Medical Need



Immunome analysis of the Cancer Genome Atlas (TCGA) data from Firehouse Legacy dataset

Immunome Data – Directly Confirms IL-38 Expression in Primary Patient Tumors by IHC



IL-38 Expression in Solid Tumors

IL-38 is Associated with Reduced Immune Cell Infiltration

IL-38 Overexpression Inhibits Infiltration of T cells into Tumors In Vivo







Kinoshita *et al, Cancer Immunol. Immunother.*(2021) 70:123

High IL-38 Expression is Associated with Reduced Immune Cell Infiltration

- IL-38 high tumor samples correlate with reduced infiltration of multiple immune subsets, especially in H&N, lung and esophageal cancers



Immunome analysis of the Cancer Genome Atlas (TCGA) data from Firehouse Legacy dataset

IMM-ONC-01

Blocking IL-38 Leads to Tumor Control in Two Different Tumor Models

Demonstration of Anti-Tumor Activity (B16F10 Model)

- Immunologically cold tumor model
- IMM-ONC-01 significantly inhibits B16.F10 tumor growth *in vivo* at 10 or 50 mg/Kg doses



* $p < 0.05$

Induction of Anti-Tumor Memory (EMT6 Model)

- ~40% response rate upon treatment with IMM-ONC-01
- Animals with complete cures resistant to tumor re-challenge
  - » Strongly suggests immunological memory
  - » Consistent with indirect effect on T cells



IMM-ONC-01 Program Summary – Modulating Innate Anti-Tumor Immunity

IMM-ONC-01 is a Novel Antibody Candidate Targeting IL-38

- IL-38 is a novel checkpoint in the innate immune system
- Targeting IL-38 using IMM-ONC-01 expected to boost anti-tumor immunity
- Preclinical research confirms the mechanism of action, and demonstrates efficacy, even as a monotherapy
  - » Potential indications include lung, head and neck, melanoma and prostate
- **IND filing anticipated in Q1 2022**



huIgG (PDB 1HZH)[1]

1. Crystal Structure: Research Collaboratory for Structural Bioinformatics Protein Data Bank (rcsb.org): PDB 1HZH

Immunome "At A Glance"

Proprietary Discovery Engine

Rapid, Unbiased Interrogation of Patient Memory B Cells

Applicable Across Multiple Therapeutic Areas

ADVANCING CLINICAL PROGRAMS

IMM-BCP-01 Treatment of COVID-19

IND Submission Q4 2021
Topline Data H1 2022

- Three antibody cocktail
- Binds to three non-overlapping regions of the spike protein
- ACE2 and Non ACE2 dependent neutralization
- Potent Effector Function – potential for viral clearance

IMM-ONC-01 Treatment of Solid Tumors: Targeting IL-38

IND submission Q1 2022

- Reverses IL-38 induced dampening of anti-tumor immunity
- IL-38 is a novel innate immune checkpoint
- Potential indications include Lung, Head & Neck, Melanoma

ROBUST PIPELINE

Potential for multiple new programs and partnerships

- Multiple target rich areas of cancer biology
  - Membrane Dynamics/Exosomes
  - Antibody Drug Conjugates (ADCs)
- Anti-infectives
  - Rapid Response to new infections/outbreaks

Thank You



Immunome, Inc.
665 Stockton Drive, Suite 300 | Exton, PA 19341
610.321.3700 | www.immunome.com